Related references
Note: Only part of the references are listed.A randomized controlled trial assessing behavioral, cognitive, emotional and physiological changes resulting from a communication skills training in physicians caring for cancer patients
Yves Libert et al.
PATIENT EDUCATION AND COUNSELING (2022)
The Supportive Care Needs of Cancer Patients: a Systematic Review
Madeleine Evans Webb et al.
JOURNAL OF CANCER EDUCATION (2021)
Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
Satya Das et al.
CURRENT ONCOLOGY REPORTS (2021)
Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot
Cornelius J. Fernandez et al.
WORLD JOURNAL OF GASTROINTESTINAL SURGERY (2021)
Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States
Zihan Xu et al.
JAMA NETWORK OPEN (2021)
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
Martyn E. Caplin et al.
ENDOCRINE (2021)
Filling the gaps of patient information and comprehension
Genevieve I. C. G. Ector et al.
CURRENT OPINION IN ONCOLOGY (2020)
Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review
Elie Isenberg-Grzeda et al.
PALLIATIVE & SUPPORTIVE CARE (2020)
Patient-reported outcomes and psycho-oncological screening in hematology: a practical example of routine electronic monitoring
Jens Lehmann et al.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2020)
Symptoms, Psychosocial Factors, and Health-Related Quality of Life in Patients With Neuroendocrine Tumors An Integrative Review
Trude Haugland et al.
CANCER NURSING (2019)
A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial
Koenraad Blot et al.
PATIENT-RELATED OUTCOME MEASURES (2019)
Cancer patients' knowledge about their disease and treatment before, during and after treatment: a prospective, longitudinal study
Ola Berger et al.
BMC CANCER (2018)
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial
Jonathan Strosberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
NCCN Guidelines® Insights Neuroendocrine and Adrenal Tumors, Version 2.2018 Featured Updates to the NCCN Guidelines
Manisha H. Shah et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors
Jonathan R. Strosberg et al.
PANCREAS (2017)
Web-based information and support for patients with a newly diagnosed neuroendocrine tumor: a feasibility study
Grietje Bouma et al.
SUPPORTIVE CARE IN CANCER (2017)
Recent updates on grading and classification of neuroendocrine tumors
Joo Young Kim et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2017)
Retrospective Review of Serotonergic Medication Tolerability in Patients With Neuroendocrine Tumors With Biochemically Proven Carcinoid Syndrome
Diana D. Shi et al.
CANCER (2017)
Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study
Philippe Ruszniewski et al.
DIGESTIVE AND LIVER DISEASE (2016)
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Aaron I. Vinik et al.
ENDOCRINE PRACTICE (2016)
Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours
Caroline Martini et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2016)
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao et al.
LANCET (2016)
Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors
P. Jimenez-Fonseca et al.
CANCER AND METASTASIS REVIEWS (2015)
European reference values for the quality of life questionnaire EORTC QLQ-C30: Results of a German investigation and a summarizing analysis of six European general population normative studies
Andreas Hinz et al.
ACTA ONCOLOGICA (2014)
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn E. Caplin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Perceptions and needs of women with metastatic breast cancer: A focus on clinical trials
Zeina A. Nahleh et al.
BREAST (2013)
Information Provision and Patient Reported Outcomes in Patients with Metastasized Colorectal Cancer: Results from the PROFILES Registry
Olga Husson et al.
JOURNAL OF PALLIATIVE MEDICINE (2013)
The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic reviecw
O. Husson et al.
ANNALS OF ONCOLOGY (2011)
An international validation study of the EORTC QLQ-INFO25 questionnaire: An instrument to assess the information given to cancer patients
Juan Ignacio Arraras et al.
EUROPEAN JOURNAL OF CANCER (2010)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Information needs and experiences: An audit of UK cancer patients
Anna Cox et al.
EUROPEAN JOURNAL OF ONCOLOGY NURSING (2006)
Selective serotonin reuptake inhibitors and patients with carcinoid tumor
MD Williams et al.
PSYCHOSOMATICS (2005)
Rapid and sustained relief from the symptoms of carcinoid syndrome: Results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide
P Ruszniewski et al.
NEUROENDOCRINOLOGY (2004)
Share Paper
